Weekly high-dose calcitriol and docetaxel in patients with metastatic hormone-refractory prostate cancer previously exposed to docetaxel

Roberto Petrioli, Alessandra Pascucci, Edoardo Francini, Stefania Marsili, Angela Sciandivasci, Giovanni De Rubertis, Gabriele Barbanti, Antonio Manganelli, Francesco Salvestrini, Guido Francini

Research output: Contribution to journalArticle

Abstract

OBJECTIVE: To evaluate the activity and tolerability of weekly high-dose calcitriol and docetaxel in patients with metastatic hormone-refractory prostate cancer (HRPC) previously exposed to docetaxel, as patients who progress after docetaxel treatment might be considered for second-line chemotherapy, but with no standard salvage therapy available we hypothesised that high-dose calcitriol might restore sensitivity to chemotherapy. PATIENTS AND METHODS: The study comprised 26 patients who had progressed after first-line treatment with docetaxel-based chemotherapy had failed. Treatment cycles consisted of calcitriol (32 μg orally as 0.5 μg tablets) on day 1 and docetaxel (30 mg/m 2 intravenous) on day 2, administered for six consecutive weeks followed by a 2-week rest interval for a maximum of 24 cycles. RESULTS: There was a response in prostate-specific antigen (PSA) level in eight patients (31%); seven (27%) had a stable PSA level for ≥ 12 weeks. The median time to PSA progression was 4.2 months and the median survival was 9.3 months. The regimen was generally well tolerated; there was grade 2 hypercalcaemia, probably related to calcitriol, in one patient after six treatment cycles. CONCLUSION: Weekly high-dose calcitriol and docetaxel seems to be an effective and well-tolerated treatment option for patients with metastatic HRPC previously exposed to docetaxel-based chemotherapy.

Original languageEnglish
Pages (from-to)775-779
Number of pages5
JournalBJU International
Volume100
Issue number4
DOIs
Publication statusPublished - Oct 2007

Keywords

  • Calcitriol
  • Docetaxel
  • Hormone-refractory
  • Prostate cancer

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Weekly high-dose calcitriol and docetaxel in patients with metastatic hormone-refractory prostate cancer previously exposed to docetaxel'. Together they form a unique fingerprint.

  • Cite this

    Petrioli, R., Pascucci, A., Francini, E., Marsili, S., Sciandivasci, A., De Rubertis, G., Barbanti, G., Manganelli, A., Salvestrini, F., & Francini, G. (2007). Weekly high-dose calcitriol and docetaxel in patients with metastatic hormone-refractory prostate cancer previously exposed to docetaxel. BJU International, 100(4), 775-779. https://doi.org/10.1111/j.1464-410X.2007.07019.x